130 related articles for article (PubMed ID: 37898875)
1. A pharmacovigilance study on drug-induced liver injury associated with antibody-drug conjugates (ADCs) based on the food and drug administration adverse event reporting system.
Sun C; Yang X; Tang L; Chen J
Expert Opin Drug Saf; 2023 Oct; ():1-12. PubMed ID: 37898875
[TBL] [Abstract][Full Text] [Related]
2. A pharmacovigilance study on antibody-drug conjugate (ADC)-related neurotoxicity based on the FDA adverse event reporting system (FAERS).
Tang L; Sun C; Liu W; Wu H; Ding C
Front Pharmacol; 2024; 15():1362484. PubMed ID: 38384285
[No Abstract] [Full Text] [Related]
3. Cardiovascular adverse events associated with antibody-drug conjugates (ADCs): a pharmacovigilance study based on the FAERS database.
Long P; Li S; Pan L; Wang Y; Chen W; Wang X
Front Pharmacol; 2024; 15():1378010. PubMed ID: 38766629
[TBL] [Abstract][Full Text] [Related]
4. Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting system.
Lin W; Xu J; Liao Y; Lin X; Yang J; Zhuang W
Int J Clin Pharm; 2024 Jun; 46(3):614-622. PubMed ID: 38100054
[TBL] [Abstract][Full Text] [Related]
5. Caution the arrhythmia association with antibody-drug conjugates: a pharmacovigilance study.
Li X; Chen G; Hu Y; Zhao B; Jiang J
Anticancer Drugs; 2022 Jan; 33(1):e228-e234. PubMed ID: 34538863
[TBL] [Abstract][Full Text] [Related]
6. Adverse event profiles of drug-induced liver injury caused by antidepressant drugs: a disproportionality analysis.
Jiang A; Wei C; Zhu W; Wu F; Wu B
Ther Adv Drug Saf; 2024; 15():20420986241244585. PubMed ID: 38715707
[TBL] [Abstract][Full Text] [Related]
7. Hepatotoxicity reports in the FDA adverse event reporting system database: A comparison of drugs that cause injury
Rana P; Aleo MD; Wen X; Kogut S
Acta Pharm Sin B; 2021 Dec; 11(12):3857-3868. PubMed ID: 35024312
[TBL] [Abstract][Full Text] [Related]
8. A pharmacovigilance study of the association between tetracyclines and hepatotoxicity based on Food and Drug Administration adverse event reporting system data.
Wei C; Liu Y; Jiang A; Wu B
Int J Clin Pharm; 2022 Jun; 44(3):709-716. PubMed ID: 35364753
[TBL] [Abstract][Full Text] [Related]
9. Do antibody-drug conjugates increase the risk of sepsis in cancer patients? A pharmacovigilance study.
Xia S; Zhao YC; Guo L; Gong H; Wang YK; Ma R; Zhang BK; Sheng Y; Sarangdhar M; Noguchi Y; Yan M
Front Pharmacol; 2022; 13():967017. PubMed ID: 36467034
[No Abstract] [Full Text] [Related]
10. Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System from 2004 to 2021.
Jiang T; Su H; Xu J; Li C; Zhang N; Li Y; Wu Y; Ni R; Ming Y; Li Z; Li L; Liu Y
Ther Adv Drug Saf; 2024; 15():20420986231224227. PubMed ID: 38293566
[TBL] [Abstract][Full Text] [Related]
11. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system.
Raschi E; Poluzzi E; Koci A; Salvo F; Pariente A; Biselli M; Moretti U; Moore N; De Ponti F
Br J Clin Pharmacol; 2015 Aug; 80(2):285-93. PubMed ID: 25689417
[TBL] [Abstract][Full Text] [Related]
12. Drug-induced liver injury associated with antiseizure medications from the FDA Adverse Event Reporting System (FAERS).
Kamitaki BK; Minacapelli CD; Zhang P; Wachuku C; Gupta K; Catalano C; Rustgi V
Epilepsy Behav; 2021 Apr; 117():107832. PubMed ID: 33626490
[TBL] [Abstract][Full Text] [Related]
13. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.
Brinker AD; Lyndly J; Tonning J; Moeny D; Levine JG; Avigan MI
Drug Saf; 2013 Dec; 36(12):1169-78. PubMed ID: 24178291
[TBL] [Abstract][Full Text] [Related]
14. Adverse Event Profile Differences between Trastuzumab Emtansine and Trastuzumab Deruxtecan: A Real-world, Pharmacovigilance Study.
Liu F; Yin G; Xue S; Rehman FU; Liao D; Pan Y
J Cancer; 2023; 14(17):3275-3284. PubMed ID: 37928419
[No Abstract] [Full Text] [Related]
15. A real-world pharmacovigilance analysis of the FDA adverse event reporting system events for polatuzumab vedotin.
Xu Z; Huang D; Liu Q; Liu S; Liu J; Wang H; Shen Z
Expert Opin Drug Saf; 2024 May; ():1-9. PubMed ID: 38695550
[TBL] [Abstract][Full Text] [Related]
16. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
17. Drug-induced torsades de pointes: Disproportionality analysis of the United States Food and Drug Administration adverse event reporting system.
Wu Z; Zhou P; He N; Zhai S
Front Cardiovasc Med; 2022; 9():966331. PubMed ID: 36352852
[TBL] [Abstract][Full Text] [Related]
18. Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system.
Chen JJ; Huo XC; Wang SX; Wang F; Zhao Q
Int J Clin Pharm; 2022 Dec; 44(6):1351-1360. PubMed ID: 36178607
[TBL] [Abstract][Full Text] [Related]
19. Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database.
Altebainawi AF; Alfaraj LA; Alharbi AA; Alkhuraisi FF; Alshammari TM
Ther Adv Drug Saf; 2023; 14():20420986231154075. PubMed ID: 36875514
[TBL] [Abstract][Full Text] [Related]
20. High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive/mutated malignancies: a pharmacovigilance study based on the FAERS database.
Ma P; Tian H; Shi Q; Liu R; Zhang Y; Qi X; Chen Y
Expert Opin Drug Saf; 2023; 22(8):685-696. PubMed ID: 37068935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
